Earnings call transcript: Cryoport Q4 2025 misses EPS, stock rises on revenue beat

Cryoport beat Q4 2025 revenue expectations with $45.45M versus a $42.93M consensus (+5.87%) but missed on EPS at -$0.27 versus -$0.21 forecast (28.6% negative surprise). Gross margin improved to 47% and adjusted EBITDA rose $12M YoY; management guided 2026 revenue of $190–$194M and expects positive adjusted EBITDA in H2 2026. Shares jumped 6.46% after-hours (from $8.21 to $8.74); market cap $419M and 52-week return +35%, though profitability remains a key risk.

Analysis

Cryoport is transitioning from a transaction-heavy logistics vendor to a software-and-services platform; the latent value is in fixed-cost absorption across higher-volume commercial launches and recurring SaaS-like telemetry from CryoVerse. If the company can convert a handful of mid-size commercial programs into long-term contracts, unit economics will shift quickly because marginal shipping costs are low while pricing power for integrated cold-chain orchestration is under-penetrated.

The near-term margin path is fragile: capital-intensive site builds and customer-specific kitting are lumpy and create timing sensitivity. Execution risk is front-loaded over the next 6–18 months — missed ramps or slower-than-expected client rollouts will compress the forward EBITDA runway even if the medium-term TAM remains intact over multiple years.

Competitive dynamics favor two groups: global logistics incumbents that can bundle scale (and may win by owning last-mile relationships) and niche technology providers that monetize data and standardization. Cryoport’s partnerships reduce go-to-market friction but also hand revenue streams and client access to larger partners; that tradeoff accelerates reach but can cap margin upside unless Cryoport retains pricing control via proprietary software or regulatory lock-ins.

Monitor three leading indicators: (1) client conversion rate from clinical support to recurring commercial contracts, (2) utilization and revenue per new global supply center, and (3) software/subscription revenue cadence from CryoVerse. These will signal whether the recent positive sentiment is durable or a short-lived re-rating ahead of an execution cliff.

Key Decisions for Investors

• Long CYRX equity (size 1–2% portfolio) with 6–12 month horizon to capture commercialization-driven leverage. Use a hard 20% stop-loss; target asymmetric upside of 40–60% if H2 execution and at least two commercial rollouts scale as expected. Rationale: high optionality to commercialization events; hedge with protective puts if sizing >2%.
• Buy a CYRX 6–9 month call spread (debit) rather than naked calls to control premium decay; target strike selection roughly 10–20% out-of-the-money depending on pricing. Risk: near-term execution or regulatory binary events can wipe premium; reward: captures the anticipated EBITDA inflection with limited defined loss.
• Tactical short of near-term CYRX implied volatility: sell 30–45 day call spreads after the post-earnings pop to collect premium (size small). Rationale: earnings pop likely overshot on sentiment; downside if any sequencing delays or integration noise — limit risk by defined call spread width.
• Small long position in CAH (size 0.5–1% portfolio) with 12–24 month horizon to capture ancillary upside from supply-chain partnerships and potential service revenue wins. Stop-loss 12%; reward modest but uncorrelated defensive exposure if integration yields cross-sell to large provider networks.